Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses

Antiviral Research

Volumn 73, Issue 2, 2007, Pages 118-125

  Buckwold, Victor E ^a   Wei, Jiayi ^b   Huang, Zhuhui ^b   Huang, Chunsheng ^b   Nalca, Aysegul ^b   Wells, Jay ^b   Russell, Julie ^b   Collins, Barbara ^b   Ptak, Roger ^b   Lang, William ^c   Scribner, Curtis ^c   Blanchett, Dennis ^c   Alessi, Tom ^c   Langecker, Peter ^c  

^a Rosenstock Hall   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c Research Triangle   (United States)

Author keywords

Antiviral; Drug combination analysis; HCV RNA replicons; Omega interferon; Transcription factor profiling

Indexed keywords

ALPHA2A INTERFERON; BETA1A INTERFERON; GAMMA INTERFERON; GLYCOSYLATED OMEGA INTERFERON; RECOMBINANT INTERFERON; RECOMBINANT OMEGA INTERFERON; RIBAVIRIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BOVINE DIARRHEA VIRUS; CHO CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; ESCHERICHIA COLI; GLYCOSYLATION; HEPATITIS C VIRUS; NONHUMAN; PRIORITY JOURNAL; REPLICON; RNA VIRUS; STATISTICAL SIGNIFICANCE; UPREGULATION; VIROGENESIS; VIRUS REPLICATION; VIRUS STRAIN; WEST NILE FLAVIVIRUS; YELLOW FEVER FLAVIVIRUS;

ANIMALS; ANTIVIRAL AGENTS; CATTLE; CERCOPITHECUS AETHIOPS; CHO CELLS; CRICETINAE; CRICETULUS; DRUG COMBINATIONS; HEPACIVIRUS; HUMANS; INTERFERON TYPE I; INTERFERONS; RECOMBINANT PROTEINS; REPLICON; TRANSCRIPTION FACTORS; VERO CELLS;

BACTERIA (MICROORGANISMS); BOVINE VIRAL DIARRHEA VIRUS 1; ESCHERICHIA COLI; HEPATITIS C VIRUS; WEST NILE VIRUS; YELLOW FEVER VIRUS;

EID: 33846414313     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.08.005     Document Type: Article

References (33)

1. Adolf G.R. Human omega interferon-a review. Multiple Sclerosis 1 (1995) S44-S47
2. Anderson J.F., and Rahal J.J. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg. Infect. Dis. 8 (2002) 107-108
3. Buckwold V.E. Implications of finding synergistic in vitro drug-drug interactions between interferon-α and ribavirin for the treatment of hepatitis C virus. J. Antimicrob. Chemother. 53 (2004) 413-414
4. Buckwold V.E., Wei J., Wenzel-Mathers M., and Russell J. Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication. Antimicrob. Agents Chemother. 47 (2003) 2293-2298
5. Buckwold V.E., Lang W., Scribner C., Blanchett D., Alessi T., and Langecker P. Safety pharmacology, toxicology and pharmacokinetic assessment of recombinant human omega interferon produced from CHO-SS cells. Basic Clin. Pharmacol. Toxicol. 99 (2006) 62-70
6. Cheney I.W., Lai V.C.H., Zhong W., Brodhag T., Dempsey S., Lim C., Hong Z., Lau J.Y.N., and Tam R.C. Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons. J. Virol. 76 (2002) 11148-11154
7. Crossley M., Tsang A.P., Bieker J.J., and Orkin S.H. Regulation of the erythroid Kruppel-like factor (EKLF) gene promoter by the erythroid transcription factor GATA-1. J. Biol. Chem. 269 (1994) 15440-15444
8. Driggers P.H., Ennist D.L., Gleason S.L., Mak W.H., Marks M.S., Levi B.Z., Flanagan J.R., Appella E., and Ozato K. An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Proc. Natl. Acad. Sci. USA 87 (1990) 3743-3747
9. Frain M., Swart G., Monaci P., Nicosia A., Stampfli S., Frank R., and Cortese R. The liver-specific transcription factor LF-B1 contains a highly diverged homeobox DNA binding domain. Cell 59 (1989) 145-157
10. Glue P., Rouzier-Panis R., Raffanel C., Sabo R., Gupta S.K., Salfi M., Jacobs S., Clement R.P., and the Hepatitis C Intervention Therapy Group. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 32 (2000) 647-653
11. Gorbakov V., Kim H., Oronsky B., and Lang W. HCV RNA results from a phase II, randomized, open-label study of omega interferon (IFN) with or without ribavirin in IFN-naïve genotype 1 chronic HCV patients. AASLD Meeting (2005) 67651 (Abstract)
12. Govindarajan B., Bai X., Cynthia Cohen C., Zhong H., Kilroy S., Louis G., Moses M., and Arbiser J.K. Malignant transformation of melanocytes to melanoma by constitutive activation of MAP kinase kinase signaling. J. Biol. Chem. 278 (2003) 9790-9795
13. Guan G., Jiang G., Koch R.L., and Shechter I. Molecular cloning and functional analysis of the promoter of the human squalene synthase gene. J. Biol. Chem. 270 (1995) 21958-21965
14. Gumucio D.L., Heilstedt-Williamson H., Gray T.A., Tarle S.A., Shelton D.A., Tagle D.A., Slightom J.L., Goodman M., and Collins F.S. Phylogenetic footprinting reveals a nuclear protein which binds to silencer sequences in the human gamma and epsilon globin genes. Mol. Cell. Biol. 12 (1992) 4919-4929
15. Jiang X., Norman M., and Li X. Use of an array technology for profiling and comparing transcription factors activated by TNFalpha and PMA in HeLa cells. Biochim. Biophys. Acta 1642 (2003) 1-8
16. Jiang X., Norman M., Roth L., and Li X. Protein-DNA array-based identification of transcription factor activities regulated by interaction with the glucocorticoid receptor. J. Biol. Chem. 279 (2004) 38480-38485
17. Jordan I., Briese T., Fischer N., Yiu-Lau J., and Lipkin W.I. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J. Infect. Dis. 182 (2000) 1214-1217
18. Karpusas M., Nolte M., Benton C.B., Meier W., Lipscomb W.N., and Goelz S. The crystal structure of human interferon beta at 2.2-A resolution. Proc. Natl. Acad. Sci. USA 94 (1997) 11813-11818
19. Larrat S., Stanke-Labesque F., Plages A., Zarski J.-P., Bessard G., and Souvignet C. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob. Agents Chemother. 47 (2003) 124-129
20. Liang T.J., Rehermann B., Seeff L.B., and Hoofnagle J.H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Int. Med. 132 (2000) 296-305
21. Lo K., Landau N.R., and Smale S.T. LyF-1, a transcriptional regulator that interacts with a novel class of promoters for lymphocyte-specific genes. Mol. Cell. Biol. 11 (1991) 5229-5243
22. Martell M., Gómez J., Esteban J.I., Sauleda S., Quer J., Cabot B., Esteban R., and Guardia J. High-throughput real-time reverse transcription-PCR quantitation of heaptitis C virus RNA. J. Clin. Microbiol. 37 (1999) 327-332
23. Morrey J.D., Smee D.F., Sidwell R.W., and Tseng C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res. 55 (2002) 107-116
24. Miura N., Kakinuma H., Sato M., Aiba N., Terada K., and Sugiyama T. Mouse forkhead (winged helix) gene LUN encodes a transactivator that acts in the lung. Genomics 50 (1998) 346-356
25. Okuse C., Rinaudo J.A., Farrar K., Wells F., and Korba B.E. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy. Antiviral Res. 65 (2005) 23-34
26. Pearlman B.L. Hepatitis C treatment update. Am. J. Med. 117 (2004) 344-352
27. Pietschmann T., Lohmann V., Kaul A., Krieger N., Rinck G., Rutter G., Strand D., and Bartenschlager R. Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J. Virol. 76 (2002) 4008-4021
28. Plauth, M., Jetschmann, J.-U., Meisel, H., Langecker, P.J., Moran, M., Lang, W., Blanchett, D., Brack, J., Von Wussow, P., 2002. Open-label study of omega interferon in previously untreated HCV-infected patients. In: Proceedings of the 37th Annual Meeting EASL (Abstract 208).
29. Scott L.J., and Perry C.M. Interferon-α-2b plus ribavirin. A review of its use in the management of chronic hepatitis C. Drugs 62 (2002) 507-556
30. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Ann. Rev. Biochem. 67 (1998) 227-264
31. Tsubota A., Akuta N., Suzuki F., Suzuki Y., Someya T., Kobayashi M., Arase Y., Saitoh S., Ikeda K., and Kumada H. Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load. Intervirology 45 (2002) 33-42
32. Walter M.R. Three-dimensional models of interferon-alpha subtypes IFN-con1, IFN-alpha8, and IFN-alpha1 derived from the crystal structure of IFN-alpha2b. Semin. Oncol. 24 (1997) 52-62
33. Ye J., Cippitelli M., Dorman L., Ortaldo J.R., and Young H.A. The nuclear factor YY1 suppresses the human gamma interferon promoter through two mechanisms: inhibition of AP1 binding and activation of a silencer element. Mol. Cell. Biol. 16 (1996) 4744-4753